The double-blind, randomized and controlled trial is expected to compare two dose levels of CF101 to placebo.
The company anticipates to recruit around 300 patients at 17 centers.
Can-Fite CEO Fishman said the positive data from the previous Phase 2 study as well as the safety profile of CF101 indicates the potential of this innovative oral treatment for the treatment of psoriasis.